Influx Healthtech Reports Strong Financial Results for FY26, Driven by Robust Nutraceutical Growth

Influx Healthtech Reports Strong Financial Results for FY26, Driven by Robust Nutraceutical Growth​

Influx Healthtech Limited announced its audited standalone and consolidated financial results for the half year and full year ended March 31, 2026. The company reported significant year-on-year increases across key revenue and profitability metrics, highlighting strong market traction in its core segments.

Financial Performance Highlights​

The financial results for the period ending March 31, 2026, show substantial growth metrics. The data, presented in ₹ lakhs unless otherwise mentioned, is summarized below:

Operational and Segment Performance​

The company noted that revenue from operations reached ₹ 8,006.90 lakhs for H2 FY26, marking 41% year-on-year growth. Full-year FY26 revenues climbed to ₹ 14,683.36 lakhs, representing a 40.0% year-on-year increase.

In terms of profitability, EBITDA stood at ₹ 1,519.92 lakhs for H2 FY26 (up 32.5% YoY) and reached ₹ 2,986.13 lakhs for the full year (up 45.2% YoY). Net Profit (PAT) for H2 FY26 was ₹ 1,054.59 lakhs (up 37.9% YoY), with full-year PAT reaching ₹ 2,054.13 lakhs, showing a 54.3% year-on-year rise. Earnings Per Share (EPS) also reflected strong performance, recording ₹ 4.56 for H2 FY26 and ₹ 9.35 for FY26.

Segment performance was characterized by the dominance of the Nutraceuticals segment, which accounted for approximately 90% of FY26 revenue. This segment saw a strong growth of 40.3% YoY, contributing ₹ 13,190.58 lakhs. The Ayurvedic segment demonstrated significant momentum, achieving an 88.9% YoY growth to ₹ 611.77 lakhs in FY26. Meanwhile, the Cosmetics segment recorded steady growth, with FY26 revenue increasing 15.8% YoY to ₹ 742.42 lakhs.

Key Operational and Strategic Initiatives​

On the operational front, the company strengthened its regulatory compliance by securing a 5-year FSSAI license for its new rented facility dedicated to manufacturing health and dietary supplements.

The company also focused on capacity enhancement and product expansion:

• An investment of ₹ 60 lakhs was made to boost tablet capacity from 20,000 to 30,000-35,000 bottles per day.
• The introduction of the Quick Snap Machine enhanced operational efficiency and production capabilities.
• Influx received the Good Manufacturing Practices (GMP) compliance approval, enabling expansion into the Tanzania market.
• The company expanded its product portfolio by incorporating Olahey Wellness Private Limited with a ₹ 1,00,000 cash investment, focusing on manufacturing Ready-to-Drink wellness beverages.

Global and Future Outlook​

Management highlighted that the robust growth in FY26 was fueled by strategic expansion, innovation, and market diversification across its nutraceutical and pharmaceutical CDMO segments.

On the international front, Influx successfully received approval for the Tanzania market, strengthening its African footprint alongside Nigeria. The company is also progressing plans to establish manufacturing operations in the UAE through RAKEZ, Ras Al Khaimah. Furthermore, the company’s capex program remains on track, with IPO-funded machinery installations expected to boost production capacity across various formats. Looking ahead, Influx plans to expand into the pet nutrition and wellness segment through a dedicated subsidiary.

INFLUX Stock Price Movement​

Influx Healthtech Limited shares today slipped by 15.26% to settle at ₹236.75. The stock traded on a volume of 399,600 shares during the session, reflecting significant selling pressure.